Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HX008 + Irinotecan |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HX008 | HX-008|HX 008|Pucotenlimab | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | HX008 is a monoclonal antibody that binds to PD-1 (PDCD1) and blocks its interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), inhibiting downstream signaling and potentially leading to activation of T-cell-mediated immune response against tumor cells and inhibition of tumor growth (PMID: 32106752). | |
| Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | stomach cancer | unknown | HX008 + Irinotecan | Phase II | Actionable | In a Phase II trial, CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients treated with HX008 and Camptosar (irinotecan) achieved an objective response rate (ORR) of 38.5% (5/13), disease control rate (DCR) of 84.6% (11/13), median progression-free survival (mPFS) of 4.3 mo, and median overall survival (mOS) was not reached, compared to CD274 (PD-L1) negative patients with an ORR of 37.5% (3/8), DCR of 75% (6/8), mPFS of 5.0 mo, and mOS of 8.7 mo (PMID: 33060149; NCT03704246). | 33060149 |
| CD274 positive | gastroesophageal junction adenocarcinoma | unknown | HX008 + Irinotecan | Phase II | Actionable | In a Phase II trial, CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients treated with HX008 and Camptosar (irinotecan) achieved an objective response rate (ORR) of 38.5% (5/13), disease control rate (DCR) of 84.6% (11/13), median progression-free survival (mPFS) of 4.3 mo, and median overall survival (mOS) was not reached, compared to CD274 (PD-L1) negative patients with an ORR of 37.5% (3/8), DCR of 75% (6/8), mPFS of 5.0 mo, and mOS of 8.7 mo (PMID: 33060149; NCT03704246). | 33060149 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST